Peptide Show

Ten peptide vials in a Ziploc bag. No labels. 

One of Dr Edwin Lee’s sons took the photo at college. The vials belonged to his roommate, who was into peptides. There was no way to tell what was in them. At a swimming pool, a 22-year-old lifeguard told Edwin he was using peptides too. Edwin reckoned the lifeguard knew more about them than many doctors. 

Edwin is an endocrinologist and co-founder of the Clinical Peptide Society, where he teaches clinicians about peptides. 

He joins Richard Skaife to talk about what patients are already trying, what doctors are being asked to prescribe, and what happens when someone has a side effect and nobody records it. 

He explains

■ What a “yes” from FDA advisers means for peptides such as BPC-157 and Epitalon
■ Why he wants a registry that makes peptide side effects visible
■ Why he starts with sleep, nutrition, and hormones before introducing peptides in his own practice
■ What he’d want a larger human trial to answer about SS-31 and diabetic kidney disease
■ How he’d test BPC-157 and thymosin beta 4 for knee injuries to see whether either works alone, whether the combination works better, or whether placebo tells a different story

Chapters

  • (00:00) - Intro
  • (00:40) - Meet Dr Edwin Lee
  • (02:01) - How Edwin got into peptides
  • (04:25) - How the peptide gray market took off
  • (05:58) - What does a “yes” from FDA advisers mean?
  • (09:18) - Are doctors keeping up with peptides?
  • (14:22) - Who’s tracking peptide side effects?
  • (17:03) - Sleep, hormones, and Edwin’s approach
  • (20:55) - When patients ask for peptides by name
  • (22:07) - The human trials Edwin would run
  • (24:19) - Could peptides become a $100 billion market?

Watch the full episode on YouTube

Further reading

FDA. The July 2026 advisory meeting materials name the seven peptide groups under consideration and the uses the FDA reviewed for each. Read the FDA meeting materials

Dinetz and Lee. Edwin co-authored a narrative review of human studies on thymosin alpha 1, the peptide he discusses from an earlier FDA advisory meeting. Read the review on PubMed

FDA MedWatch. The FDA’s existing reporting program accepts reports from patients and health professionals about suspected serious reactions and product quality problems. See how MedWatch works

Follow Dr Edwin Lee

Clinical Peptide Society: Edwin Lee’s profile

Follow Richard Skaife

LinkedIn: linkedin.com/in/richardskaife/

Peptide Show

Website: Peptide.Show
Instagram: @Peptide.Show
TikTok: @peptide.show
Facebook: Peptide Show
X: @peptideshow
YouTube: @PeptideShow

Peptide Show explores the science, medicine, business, and people shaping the rapidly evolving world of peptides.

Presented by Longr: longr.io

Follow Peptide Show for new episodes every Tuesday.

This podcast is for informational and educational purposes only. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements.

Creators and Guests

Host
Richard Skaife
Entrepreneur, Venture Capitalist and CEO of Longr, focused on longevity, health technology and emerging science.
Guest
Dr Edwin Lee
Dr. Edwin Lee is a physician, bestselling author and international speaker who - thanks in part to his groundbreaking insight in his field, and his many significant presentations at major medical conferences around the world - is a respected proponent and authority on hormonal balance and wellness, and a leader in defining the future of regenerative and functional medicine.
Editor
Toby Sorabjee
Co-founder and COO of Longr, working across longevity, health technology, investing and media.

What is Peptide Show?

Welcome to the world of Peptides. New episodes every Tuesday.

Just yesterday I was in the swimming pool

and talking to a 22-year-old lifeguard

who was using peptides. So

I think he knew more about peptides

than a lot of conventional medicine
doctors.

A Ziploc bag of, like, 10 vials, but no
label.

You have no idea what it was.

So it's like, “What are you taking? And is
it safe?”

Hey, let's have a registry

so that if someone has a side effect

we know about it

rather than it's, like, swept underneath
the rug.

Thanks for tuning in to Peptide Show.

If you enjoy the episode,

hit subscribe and join us for the next
one.

It's the easiest thing you'll add to your
stack

this week.

Imagine you're a doctor.

Your patient spent days reading up on
BPC-157

and wants to know what you think.

You've got 10 minutes. What do you say?

Dr. Edwin Lee is an endocrinologist

who teaches other doctors about peptides.

In December 2024, he stood in front of FDA
advisers

to make the case for one called

thymosin alpha 1.

Seventeen voted against. Four voted for
it.

Fast-forward to today,

and the peptide landscape is very
different.

Edwin calls his 84-year-old mother a
“peptide junkie.”

In his own clinic he says,

he might wait until the second or third

visit to bring up peptides.

So what does he want to know about a
patient

before he gets that far? My guest today is
Dr.

Edwin Lee. Welcome to Peptide Show.

Welcome to Peptide Show from Longr.

My name is Richard Skaife.

I'm a venture capitalist and entrepreneur.

And on the podcast,

we explore the world of the business of
peptides.

On today's show, Dr. Edwin Lee.

He's an endocrinologist who

found his way into peptide therapy. Edwin,

thank you very much for joining us on
Peptide Show.

Yeah, thank you very much for inviting me.

Tell me a little bit about your journey,

starting off as an endocrinologist.

You've authored a number of books.

You're a thought leader and practitioner
in

the peptide therapy space.

How did that journey come about?

Sometimes I wonder about how

how, how I got here.

So it's an amazing

journey. But

I fell in love with endocrinology and did
a fellowship

at the University of Pittsburgh,

but I also did critical care since I love
both

the ICU and endocrinology. Very,

very unique, totally opposite spectrums of
the world.

And then I eventually had to

decide which direction I was gonna go
into.

So I ended up in endocrinology and, uh,

did conventional, uh,

endocrinology in,

or in actually a small town called Winter
Haven,

Florida. And then I got tired of
conventional endocrinology

and I got into

functional medicine and went that route

over time.

Probably 10 years later,

I got introduced to peptides.

So I've been doing peptides for about 10
years now.

And so I've been, like, I've

been fortunate to be ahead of the curve,
and

I've been able to publish some studies

and publish a book on…

The book is called The Fountain of Youth
with Peptides.

So it's also on Amazon, the

electronic version of it.

But, uh,

I also formed the committee,

the organization SavePeptides.org, because

once I started using peptides, I noticed
the

the power of the regenerative peptides.

And it's like, “This has to be saved,”

and it's where I think

a lot of patients can benefit

from using these peptides.

And we do need more studies

to show safety and efficacy,

But it's, it's amazing that

peptides are very popular on college
campuses.

And just yesterday I was in the swimming
pool

and talking to a 22-year-old lifeguard

who was using peptides. So

I think he knew more about peptides

than a lot of conventional medicine
doctors,

'cause we kinda got deep.

I think that's a really good observation.

I mean, it does feel that we've

we've reached, um,

perhaps sort of peak peptide mania,

um, and,

and that obviously brings,

you know, with it

its own set of challenges

in terms of the quality of information,

which is,

you know, going out there into,

into predominantly social media.

What would you say have been the

sort of the big changes that you've seen
over the,

the 10

years that you've been working with them
professionally?

Well, the gray market

really exploded with a lot of

social influencers and uh,

it's, it's…

It's good that the word has been out, but

the danger is there are a lot of

stuff that, well,

a lot of peptides that, they're not even
labeled. You,

you have no idea what it is. My,

my son is in… Both of them are in college,
and one

took a picture of this, of his roommate,

that was, uh,

basically into peptides. And it was a
whole bag,

a Ziploc bag of, like, 10 vials,

[unclear], but no label.

You have no idea what it was.

So it's like, “What are you taking? And is
it safe?”

So that's the whole idea, is we have to
have it safe.

'Cause if someone dies from peptides,

then the whole

basically world of peptides can go down
quickly.

So I don't want anyone to die from
peptides.

So… And obviously,

you know, there is potential for,

you know, a number of peptides to be,

to be moved onto the compound…

should be moved onto the compounding list.

And there's a lot of confusion

in terms of, you know, what that means and

and what,

you know, happened

with the PCAC

quite recently. For those in

the audience who've,

you know, never sort of gone through that
before,

could you explain a little bit about what
that

process involved and your understanding of
it?

Yeah, so just to make it simple,

there was a big meeting on July 23rd,

24th, on seven peptides,

and the meeting was called the Pharmacy

Compounding Advisory Committee meeting.

So, PCAC, P-C-A-C,

and it's an advisory committee to the FDA.

And they,

they review basically the literature of
each peptide

and then they vote on each peptide

right then and there after,

after, um,

both sides discuss it.

So it's not really a fair discussion
'cause

I was there in December of 2024,

and I was trying to save thymosin alpha 1,

which has the best data out there.

I even published a study,

basically the comprehensive review

of the safety and efficacy of

thymosin alpha 1 in human clinical trials.

So I tabulated over 11,000,

uh, so, um,

humans worldwide being on thymosin alpha
1.

And at the end of the meeting,

it got voted and we lost. Seventeen said
no.

Four said yes. So

thymosin alpha 1 cannot be compounded
through a

503A compounding pharmacy. So, uh,

this July, we had seven peptides.

Six out of seven passed. And it's really
interesting.

It was eight that said yes, six said no,

and one basically abstained.

But each one was basically eight–six,

eight–six,

eight–six.

There was one that did not pass.

It was DSIP, delta sleep-inducing peptide.

I don't think it really works that well.

But anyway, some people like it.

But there are other things that can help
you sleep

besides DSIP.

But I didn't cry over that.

But I was so happy that

BPC-157,

one of my favorite peptides, and Epitalon

basically passed. Those,

those two are really dear

to my heart, and I'm glad that the PCAC

said yes. Now, it doesn't mean that it's
legal.

We have to wait for the FDA

to make their final decision.

So they could basically take a year

and review all the data, and then they,

they basically can take the PCAC advisory

recommendation that it's okay, and they
can,

they usually agree with it, but the FDA
can also say no.

“Uh, we don't agree with it.

We don't agree with what the PCAC

advisory committee said. We're gonna say
no.”

So, most likely it'll say yes, 'cause RFK
Jr.,

I'm sure he has some influence on the FDA.

Absolutely. Now, you,

you made a really good observation

earlier on

around one of your friends,

you know, one of your son's friends having
a,

you know, probably, was it the lifeguard?
Having more,

more insights into peptides than,

you know, most medical professionals.
Where,

where do, where do you think we,

we stand in terms of the awareness of,

of peptides in terms of the,

the medical community?

I think the medical community is really
behind

because I have some friends that,

their parents have a stroke,

and they go, they,

they accompany their parents to the
neurologist

or general practitioner and will say,
“Well,

“What about Cerebrolysin?” And they go,

“I've never heard of it.” So it's,

you know, avoided. So, but

Cerebrolysin, you probably know,

it's approved in over 50 countries and
phenomenal

to help with stroke

and especially also with dementia too. So,
um…

And unfortunately,

my friend's father is just going downhill.

And I mean, he wants to give it,

but his mother is really into conventional
medicine and

wants the

the neurologist to give the okay. And it's
like, well,

you know, I don't,

you know,

if you want to use it, then, uh,

if you're for it,

then I'll be glad to treat it. But, you
know,

I'm not, I don't want to spend, like, two,

two days to try to convince you

to use it. So either, you know,

you believe it or you're not. If you
don't,

so…

And what do you think needs to happen

for more medical professionals,

people who are sitting at the sort of the,

the front end of care, to,

to, uh,

you know, to have a better understanding
of peptides?

I think, um,

since this recent PCAC

meeting was favorable to peptides,

I think more doctors are probably gonna be
looking

for more education.

So I'm a co-founder of Clinical Peptide
Society, and

my, my,

my friend and colleague, Dr. Luis
Martinez,

we actually formed this organization. So
we,

we teach worldwide, on people,

on a lot of doctors, on healthcare
providers,

on how to use peptides properly.

And, anyway, we have a class September
11th, and

since the PCAC meeting got approved,

we have uptake in people signing up for
the class.

So it's really, I think that, uh,

there, we're not the only organization.

International Peptide Society offers it.

Dr. Seeds' organization offers it. Now
there,

there's a couple more different
organizations

that are out there. But anyway,

I, I,

I just love to teach,

you know, healthcare providers on these
peptides,

and hopefully they can teach their friends
and all that,

too. So I was just recently in Mexico City
teaching,

and we taught over 100 doctors from
Mexico.

And they're not only from Mexico,

but they were from like Costa Rica and
Venezuela

and Colombia and other,

other, Panama and different countries
there too.

So we'll be planning to go to Brazil,

and I go to Bangkok, uh,

in mid-August. I'll teach there too.

So, um,

my schedule is pretty busy

in terms of teaching other doctors.

I don't… Absolutely. And what would you
say is the,

the, the

sort of the biggest

apprehension that doctors have at the
moment

in terms of their willingness to
prescribe?

And is there any sort of common,

you know, safety

um, issues that you,

you bump into in terms of the way that
people are

describing the protocols that they're
running?

What are the sort of the common things
that you,

you see as a theme, or…?

I think the biggest issue is they have no
idea,

you know,

these different peptides. They just come
in

just with a blank slate.

And when they finish a day class, there's,

they're usually very excited.

So we usually say start off with two or
three peptides,

um, thymosin alpha 1, and

you know, tons of data there, and,

or maybe with BPC, which I,

I find it to be absolutely safe.

And it's really amazing how regenerative
it is. Or, uh,

GHK,

which is also natural. Tons of data there,
literature.

So, um,

just start with some safe peptides

and then once you learn

then you can go on to learn other
peptides.

So, um,

I think we teach, like, in a day class,

probably 45 different peptides.

So it's hard to,

you can't incorporate all 45 the next day.

So, I mean, there's,

there's, you know,

many different peptides and it'll,

it'll take a while for someone

to get proficient in learning how to use
all of it,

use all…

And alongside that

sort of an initial prescribing decision,

are there other things which doctors
should be

building into their,

their prescribing protocols,

their monitoring and their safety
protocols?

Well, in general,

I mean, even before you prescribe a
peptide,

I think you have to get the “environment”
correct.

So you really need good nutrition.

You need to have the person to sleep well,

and basically hydration and nutrition.

And it's, it's,

it's really kind of get the foundation

really solid with hormone balancing, and,
um,

it's…

Once you get that, and then you can add
some peptides,

I think you'll get added benefit.

But yes, I mean, if…

I mean, your question is,

“Should you monitor side effects?”

Of course. I mean, I,

that's why I think the FDA really wants,

I want somebody to step up and say, “Hey,

let's have a registry

so that if someone has a side effect,

we know about it rather than

it's like

swept underneath the rug.” 'Cause we need
to collect data.

That's the whole thing. And, um,

it's gonna take a group effort to,

to start a registry, and

it should be open book,

and everyone should see it and all that.

Because everyone's different.

So… Indeed. And I think that is one of
the,

the challenges with, you know,

the sort of ever-advancing gray market.

It's not just the,

the quality issue, but it's the fact that,

you know, people are self-prescribing,

and that must be quite concerning for you

as a medical professional,

but also for,

for regulators who are,

who are supervising the environment.

Yeah, I just don't know how the FDA is
gonna

regulate all this 'cause they're
understaffed, and it's,

it's really like the genie's outside the
bottle now.

So, um, it's…

there's gonna be some bad apples out
there.

So I don't, I think the gray market will
still be there,

but what's amazing is Peptide Sciences,

the largest, uh,

online peptide, uh,

store, they got shut down, um,

I think in March or May of 2026.

And now there's all these, like,

fake Peptide Sciences that

use their website and they use their
pictures,

but it's not them. It's something else.

So how do you, how do you control…?

How do you police it? Yeah.

Diving back into your work as a physician,

one of the things you touched on so
briefly was,

was, you know,

looking at hormones. How do you sit that
alongside

peptide therapy?

Explaining it to somebody who's not a
physician,

what is the significance there?

Uh, well,

when I see a patient,

they come in generally as a package.

So, um,

they have,

whether their issue is hormonal imbalance,
that,

you know, they're irritable,

they don't sleep well, they want to lose
weight,

they basically have low energy.

I try to work on sleep and, um,

I, you know,

address,

you know, some of their top issues.

And then we come…

When they come back, we look at their
hormones,

and I usually kind of know which hormones
are

usually out of whack. But sometimes they,

they want to see their lab work before
they start

HRT therapy. And, uh,

generally over time, maybe on the second
or third visit,

we'll maybe introduce one or,

one peptide or something like that

to address a certain issue.

Um, so,

you know, there is an interesting peptide
that

I'll be talking about later tonight.

There's a company out there that uses AI

in the plant world to just find these,

to figure out what these peptides

in the plant world can do to humans.

So there is a peptide, basically it's
called, um…

And the product is called SLEEPgevity,

which is really interesting.

It's, it's, they,

they found a peptide in brown rice

to help people sleep better.

and it has no melatonin in this product,

but it actually, this peptide

can activate the pathway called the orexin
pathway.

And it lowers cortisol spikes at
nighttime.

So when people sleep

and then they wake up because their mind's
racing,

it's because their cortisol's

spiking in the middle of the night.

And there's a lot of people just,

you know, they can't turn off their brain.

They have monkey brain.

They're just, you know,

trying to figure out everything,

and then they're exhausted because,

you know, by the time they fall back to
sleep,

it's, you know, time to get up.

So, um, this is, this oral peptide is
amazing

because it's plant-based,

and I have a lot of great results in my
patients.

So if you can sleep better,

you can fix your adrenal fatigue,

your growth hormone will go up

because you need dream sleep.

If you have good REM sleep,

you know,

you're gonna have that restorative part of
your body

to heal and then your growth hormone goes
up.

But if you sleep lousy, everything,

you know, tends to fall apart.

So you need to restore your body
naturally. And

whether, you know, it's progesterone for
women,

or you need some oxytocin or

you know, you use some other

things that can help the sleep pathway,

I think that's key. And so there,

there are peptides by mouth and there's,

there's other peptides you,

you know, you can inject. But, you know,

there's really some interesting things

like with Epitalon, can help with the
sleep cycle.

There's three genes that it,

it's involved with the melatonin
production.

So if you can turn on your natural
melatonin,

I think that will really help there too.

So, but usually I don't talk about
peptides

until a little later on their,

on their journey of health,

so unless you come in just for, like,

“I have a shoulder tear,”

you know, a specific, like we call a
peptide consult,

you know, you're

here for injection, then yes,

we'll talk about that.

But… And you must have, I mean, given,

given the way that, you know,

so many people, and this is what

I think could be a real change in
medicine,

of sort of self-selected with,

with GLP-1s,

and, you know, that self-selection is,

has tended to be,

what their next-door neighbor is using

and what's working well.

So this must be a sort of, quite a sort of
a,

a sort of a,

a landscape change for you as a medical
practitioner,

in terms of people coming to you and

almost telling you what they want?

Well, um,

I have a lot of very smart,

intelligent people, so most of them read a
lot,

but they get confused on the internet. And

in a way,

it's okay because I can kind of hear what
they want,

and we can,

you know, choose to try one or two and go
that way.

But I'm, I mean, I like the,

I like my patients to be educated

and it's just easier to move on

rather than to start from the very
beginning,

“What is a peptide?” and to go from there.

So, by the way, my mother, who's 84, she's
a “peptide junkie.”

She loves peptides.

The grandmother stack. Yes.

Absolutely. Two final questions before we
wrap things up.

If you had an unlimited budget

to run human trials, what peptides would
you put into

those trials, and why would you pick them?

The ones you wanna see the most human data
on.

Well,

I was gonna say SS-31,

but there is tons of data on SS-31.

But I would like to see more data with
SS-31

reversing…

Hopefully, you can reverse kidney failure.

Um, so, uh,

I have some patients that,

few patients are getting better with
renal,

with, from their diabetic, you know,
kidney issues.

But I'd like to see more.

I have very few patients, so I can't… It's
like, you know,

three patients.

But it'd be great to see, like, 100 or 200
patients

with that. Um…

The other thing is, um,

it's, it's, we need data with thymosin
beta 4,

TB4. I mean, there are very few studies,

but it'd be great for musculoskeletal.

Which is better? Is it BPC?

Is it TB4 or is it the combination?

So it'd be, I,

it'd be really cool to do, like, a
three-arm study where,

you know, you have people with, let's say,
a meniscus

tear or ACL tear. It's a specific knee
issue.

And then you, you, you be, or, um,

or you can look at osteoarthritis.

So, so the thing is that, you know,

you give, like, a third of the group

BPC, a third of the group

TB4, and a third of the group you do a
combo,

but you also need a placebo group too.

So, yeah, a quarter,

quarter, quarter, quarter. And then,

and then from there, you, you know,

you can do your statistics and see which
is better,

'cause, uh,

we don't know. I mean,

you know,

a lot of people do the combo of BPC and
TB4, and,

you know, which one is it?

We don't know. And, you know,

there's no one that just did TB4 by
itself.

So we have no idea. So there's a lot of
unknowns.

I mean, I could probably give you, like,
more studies,

but those are the top two.

So… Fantastic. And just to wrap things up,

10 years from now,

you can talk about,

you know, your own practice, peptides in
general,

you can do a little bit of cosmic
ordering.

What do you think the market will look
like?

What do you think we will know?

And what do you think we will realize

perhaps we got wrong?

Well, I predict, um,

that if peptides really continue to go

um, down,

it's like a rolling ball down the
mountain, that this,

it's gonna be a snowball effect.

So I think, since you mentioned

the economy of peptides,

and all that, I,

I think that, you know,

with, it's like, like in the wellness
world,

it's estimated to be a billion-dollar
industry.

Just one billion.

But in 10 years, I think it'll be 100
billion.

I could be wrong,

but it could be even more than that.

But the problem I see is, will Big Pharma
say, “No,

no, no,

no, we wanna control it”?

So that's gonna be the big decision.

Can they play fair? That's the whole
thing.

Or does Big Pharma want to control
everything

and squash the compounding pharmacy and
say, “No,

you can't do any of this. You have to do
it through us”?

Indeed. And of course,

there is some of that already happening
with, uh,

with Eli

Lilly and reta and the FDA and their
arguments

around what is a peptide and what is a
biologic. Oh, yeah.

The 40-amino-acid issue, yeah.

Anything over 40 is considered biological,

which I don't think is the true
definition.

But they, I guess one of the reasons is,

the rumor,

is that they wanted to protect the
compounding pharmacies

not to make insulin.

So that's why they threw in that 40 amino
acid.

So it's ridiculous. But anyway,

Um, what's interesting is that there is

one billion peptides in the plant world.

And with AI, I'm gonna see that,

just because we may have trouble with
current peptides,

or future peptides that that's gonna be
discovered,

may be even better than what we have
currently.

So I'm really excited about that. This,

this is, you know,

The… And, and I mean, for somebody who's,

who's spent the last 10 years

of their life in this space, you,

you must reflect and

and look at it and sometimes think,

it's almost like you spent a day in it.

It's all completely new, and there's,

there's so much that we just don't know.

Oh, yeah.

I mean, I,

I'm so proud of some of the,

those fellow “students”

who have taken the peptide certification
class,

and now they're teaching me.

This is, you know,

we teach the basics and they discover
something else,

and that's how we learn. And this is,

that's the fun part of seeing how to help
people

and try to use things that

that may be, may be natural or just
slightly tweaked,

so that they have a longer shelf life

or longer half-life so that you can have,

you know, extra benefits. So the body can
heal itself.

That's, that's,

if it's given the right kind of

ingredients and pathway.

and I think peptides are critical for it.

Well, Edward,

thank you very much for joining us on
Peptide Show.

We, uh,

wish you well in your journey of evolution
and thinking,

um and thanks very much for joining us.

Hey, it's my pleasure. Thank you very
much.